OKYO vs ALPS Comparison

OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.

ALPS Group Inc is an investment holding company involved in research and development, including stem cell and biotechnology-related business, and investing and managing businesses such as health and beauty centres and medical centres. The Company operates through Medical and Wellness, Life Science and Others segments. Medical and Wellness generates maximum revenue from non-surgical aesthetic services, surgical aesthetic services, medical consultation, health screenings, cellular therapy and research, and COVID-19 testing. Life Science provides whole-genome sequencing and pharmacogenomics, while Others comprises investment holding and provision of management services. The Company generates revenue in Malaysia.